Revision history of "Development of a bispecific antibody fragment for simultaneous cancer control and recruitment of immune system cells (BIKE)" (Q77786)

13 October 2024

• curprev 05:5005:50, 13 October 2024‎ DG Regio talk contribs‎ 82,374 bytes 0‎ ‎Changed label, description and/or aliases in pt
• curprev 05:5005:50, 13 October 2024‎ DG Regio talk contribs‎ 82,374 bytes −63‎ ‎Set a claim value: summary (P836): O objetivo deste projeto é desenvolver o primeiro fragmento de anticorpos biespecíficos da sua classe como candidato a medicamento para doentes com cancro da mama triplo negativo (TNBC), que será realizado utilizando uma estratégia terapêutica revolucionária – a chamada imunoterapia. Devido à atividade dupla, o candidato regulará simultaneamente a via de sinalização das células cancerosas, bem como ativará os mecanismos de citotoxicidade celular, pe...

20 March 2024

• curprev 13:5213:52, 20 March 2024‎ DG Regio talk contribs‎ 82,437 bytes +288‎ ‎Added qualifier: readability score (P590521): 0.7786654065183075

12 January 2024

• curprev 16:0816:08, 12 January 2024‎ DG Regio talk contribs‎ 82,149 bytes +1,083‎ ‎Changed an Item

11 June 2023

• curprev 11:1211:12, 11 June 2023‎ Admin talk contribs‎ 81,066 bytes +435‎ BatchIngestion

24 May 2023

• curprev 16:5816:58, 24 May 2023‎ DG Regio talk contribs‎ 80,631 bytes +949‎ ‎Changed an Item

2 March 2023

• curprev 22:2122:21, 2 March 2023‎ DG Regio talk contribs‎ 79,682 bytes +371‎ ‎Changed label, description and/or aliases in it, da, sk, de, fi, el, ro, lv, bg, sl, ga, fr, sv, lt, es, pt, hu, et, mt, hr, nl, and other parts

25 October 2022

• curprev 09:4509:45, 25 October 2022‎ DG Regio talk contribs‎ 79,311 bytes +841‎ ‎Changed an Item: Import item from Poland

19 October 2022

• curprev 15:2915:29, 19 October 2022‎ DG Regio talk contribs‎ 78,470 bytes +1,235‎ ‎Changed an Item: Import item from Poland
• curprev 15:2915:29, 19 October 2022‎ DG Regio talk contribs‎ 77,235 bytes −418‎ ‎Removed claim: co-financing rate (P837): 73.9 percentage
• curprev 15:2915:29, 19 October 2022‎ DG Regio talk contribs‎ 77,653 bytes −411‎ ‎Removed claim: instance of (P35): Discontinued Kohesio Project (Q4412041)
• curprev 15:2915:29, 19 October 2022‎ DG Regio talk contribs‎ 78,064 bytes −5‎ ‎Changed an Item: Continued project

17 October 2022

• curprev 15:4015:40, 17 October 2022‎ DG Regio talk contribs‎ 78,069 bytes +416‎ ‎Changed an Item: Discontinued project

13 August 2022

• curprev 16:1516:15, 13 August 2022‎ DG Regio talk contribs‎ 77,653 bytes +49,483‎ ‎Changed label, description and/or aliases in et, lt, hr, el, sk, fi, hu, cs, lv, ga, sl, bg, mt, pt, da, ro, sv, nl, fr, de, it, es, and other parts: Adding translations: et, lt, hr, el, sk, fi, hu, cs, lv, ga, sl, bg, mt, pt, da, ro, sv,

19 January 2022

• curprev 11:1411:14, 19 January 2022‎ DG Regio talk contribs‎ 28,170 bytes +2,790‎ ‎Changed label, description and/or aliases in es, and other parts: Adding Spanish translations

15 January 2022

• curprev 22:1722:17, 15 January 2022‎ DG Regio talk contribs‎ 25,380 bytes +2,738‎ ‎Changed label, description and/or aliases in it, and other parts: Adding Italian translations

16 December 2021

• curprev 19:1719:17, 16 December 2021‎ DG Regio talk contribs‎ 22,642 bytes +2,720‎ ‎Changed label, description and/or aliases in nl, and other parts: Adding Dutch translations

7 December 2021

• curprev 08:0508:05, 7 December 2021‎ DG Regio talk contribs‎ 19,922 bytes +2,680‎ ‎Changed label, description and/or aliases in de, and other parts: Adding German translations

30 November 2021

• curprev 14:2314:23, 30 November 2021‎ DG Regio talk contribs‎ 17,242 bytes +2,653‎ ‎Created claim: summary (P836): L’objectif de ce projet est de développer le fragment d’anticorps bispécifiques de première classe en tant que candidat pour un médicament pour les patients atteints d’un cancer du sein triple négatif (TNBC), qui sera réalisé avec l’utilisation d’une stratégie thérapeutique révolutionnaire — l’immunothérapie. Grâce à la double activité, le candidat au médicament régulera simultanément la voie de signalisation des cellules cancéreuses, ainsi que...
• curprev 14:2314:23, 30 November 2021‎ DG Regio talk contribs‎ 14,589 bytes +218‎ ‎Changed label, description and/or aliases in fr: translated_label

29 October 2020

• curprev 04:5404:54, 29 October 2020‎ DG Regio talk contribs‎ 14,371 bytes −406‎ ‎Removed claim: financed by (P890): Directorate-General for Regional and Urban Policy (Q8361), Removing unnecessary financed by statement
• curprev 04:5404:54, 29 October 2020‎ DG Regio talk contribs‎ 14,777 bytes −34‎ ‎Changed label, description and/or aliases in 2 languages: Changing unique label-description pair

14 October 2020

• curprev 10:2210:22, 14 October 2020‎ DG Regio talk contribs‎ 14,811 bytes +183‎ ‎Changed label, description and/or aliases in 1 language: translated_label
• curprev 10:2210:22, 14 October 2020‎ DG Regio talk contribs‎ 14,628 bytes −174‎ ‎Changed label, description and/or aliases in 1 language: remove_english_label
• curprev 10:2210:22, 14 October 2020‎ DG Regio talk contribs‎ 14,802 bytes +2,384‎ ‎Created claim: summary (P836): The aim of this project is to develop the first bispecific antibody fragment in its class as a candidate for medicine for patients with triple negative breast cancer (TNBC), which will be realised using revolutionary therapeutic strategy – so-called immunotherapy. Due to dual activity, the candidate will simultaneously regulate the signalling pathway of cancer cells, as well as activate the mechanisms of cell cytotoxicity allowing the immune sys...
• curprev 10:2210:22, 14 October 2020‎ DG Regio talk contribs‎ 12,418 bytes −1,902‎ ‎Removed claim: summary (P836): The purpose of this project is to develop the first class of bio-specific antibodies as a candidate for a medicine for patients with a triple negative breast cancer (TNBC), which will be implemented using the ‘immunotherapy’ revolution.As a result of dual activity, the candidate will also regulate the cancer signal trail at the same time, as well as to activate the cytotoxicity mechanisms that allow cancer to be actively tackled.In order to ac...

15 July 2020

• curprev 18:1218:12, 15 July 2020‎ DG Regio talk contribs‎ 14,320 bytes +429‎ ‎Changed an Item

9 June 2020

• curprev 15:1415:14, 9 June 2020‎ DG Regio talk contribs‎ 13,891 bytes +429‎ ‎Changed an Item

6 June 2020

• curprev 20:1720:17, 6 June 2020‎ DG Regio talk contribs‎ 13,462 bytes +431‎ ‎Changed an Item

26 March 2020

• curprev 10:1210:12, 26 March 2020‎ DG Regio talk contribs‎ 13,031 bytes +431‎ ‎Changed an Item

4 March 2020

• curprev 08:5708:57, 4 March 2020‎ DG Regio talk contribs‎ 12,600 bytes +1,902‎ ‎Created claim: summary (P836): The purpose of this project is to develop the first class of bio-specific antibodies as a candidate for a medicine for patients with a triple negative breast cancer (TNBC), which will be implemented using the ‘immunotherapy’ revolution.As a result of dual activity, the candidate will also regulate the cancer signal trail at the same time, as well as to activate the cytotoxicity mechanisms that allow cancer to be actively tackled.In order to achi...

18 February 2020

• curprev 07:0407:04, 18 February 2020‎ DG Regio talk contribs‎ 10,698 bytes +174‎ ‎Changed an Item: Label in wikidata changed

8 February 2020

• curprev 16:0116:01, 8 February 2020‎ DG Regio talk contribs‎ 10,524 bytes +823‎ ‎Changed an Item
• curprev 16:0116:01, 8 February 2020‎ DG Regio talk contribs‎ 9,701 bytes −417‎ ‎Removed claim: financed by (P890): European Union (Q1)

31 January 2020

• curprev 15:4115:41, 31 January 2020‎ DG Regio talk contribs‎ 10,118 bytes +1,347‎ ‎Changed an Item
• curprev 15:4115:41, 31 January 2020‎ DG Regio talk contribs‎ 8,771 bytes −844‎ ‎Removed claims
• curprev 09:4609:46, 31 January 2020‎ DG Regio talk contribs‎ 9,615 bytes +844‎ ‎Changed an Item

13 January 2020

• curprev 20:5420:54, 13 January 2020‎ DG Regio talk contribs‎ 8,771 bytes +8,771‎ ‎Created a new Item